Skip to main content
Xiaoying Yang on Muck Rack

Xiaoying Yang

As seen in: Nature, Wiley Online Library, Frontiers, MDPI, ACS Publications, Respiratory Research, Royal Society of Chemistry, Canadian Journal of Infectious Diseases & Medical Microbiology, Dove Medical Press, Dialnet - Universidad de La Rioja and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiaoying

Contact Xiaoying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

LCAL4–FUS cooperation switches on MMP13 and drives osteolytic bone metastasis in breast cancer

|
By Qiji Li, Mingjian Fan, Xiaoting Sun, Xiaoying Yang, Yuhao Zhang, Zihan Zheng, Xuan Zhang, Xian Zhang, Qingqing Zhu, Zhenchong Xiong, Kefeng Lei, Chengming Zhu, Qin Tian, Yun Wang, Meng Wang, Liping Ye
| Nature Verified
Abstract Patients with advanced breast cancer (BC) often experience bone metastasis, leading to severe skeletal complications and a significant decline in prognosis. However, the molecular mechanisms underlying BC bone metastasis remain largely unexplored. This study identified the long non-coding RNA LCAL4 as specifically upregulated in bone-metastatic BC, where it serves as an independent predictor of poor survival.
Open in Who Shared Issue with article?

Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review - Respiratory Research

|
By Humboldt-Universität zu Berlin, Pharmacology ITMP, Chula Vista, South San Francisco, Steven Kelsen, Marcus Maurer, Michael Waters, Ajit Dash, Alice Fong, Divya Mohan, Wiebke Theess, Xiaoying Yang, Giuseppe Alvaro, Christopher E. Brightling
| Respiratory Research Verified
Infections occurred in 15–45% of patients treated with astegolimab and 26–51% of patients treated with placebo, and there was no increase in rates of infections following astegolimab treatment compared with placebo (Table 1) [18, 19, 34, 35]. Importantly, no dose-dependent incidence of infections was observed in ZENYATTA (placebo, n = 65 [51.2%]; astegolimab 70 mg, n = 55 [43.3%]; astegolimab 210 mg, n = 58 [46.0%]; astegolimab 490 mg, n = 55 [45.1%]) [18].
Open in Who Shared Issue with article?

Effects of Difenoconazole and Imidacloprid Seed Coatings on Soil Microbial Community Diversity and Ecological Function

|
By Jiabin Chen, Guo Li, Xiaoying Yang, Dunfeng Feng
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?
See all 27 licensed articles (32 Total)